Congrats! Tawain Patent for GM-XAN003 Granted- A New Breakthrough in Psoriasis Treatment
The innovative drug GM-XAN003, developed by XanthoBio for the treatment of psoriasis, was granted a Taiwan patent in January 2025.
(Patent name: Application of mangosteen shell extract used in treating psoriasis; Patent No. I869637)
Psoriasis is a chronic, relapsing, immune-mediated skin disorder that significantly impacts patients’ quality of life due to symptoms such as erythema, scaling, and skin thickening. While several treatment options exist, many challenges remain. Biologics are costly, while mild to moderate cases are often managed with steroids. However, efficacy and safety limitations persist, underscoring the urgent need for innovative treatments.
GM-XAN003 harnesses the anti-inflammatory and immune-modulating properties of mangosteen shell extract, offering a promising new therapeutic option for psoriasis patients. The granting of this patent not only recognizes XanthoBio’s innovative capabilities in biotechnology research but also lays a critical foundation for future clinical progress.
XanthoBio remains committed to advancing the research and commercialization of GM-XAN003, striving to provide a safer, more effective treatment option for psoriasis patients worldwide.
Disclaimer
This article and related information on this site contain forward-looking statements. The forward-looking information requires the Company to make numerous assumptions and is subject to inherent risks, uncertainties, and other factors that are beyond the control of the Company which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company undertakes no obligation to timely inform, update, or revise the information on this site if circumstances should change.
